‌

US Patent 10835536 Therapeutic agent for FGFR inhibitor-resistant cancer

Patent 10835536 was granted and assigned to Taiho Pharmaceutical on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Taiho Pharmaceutical

Current Assignee

Taiho Pharmaceutical

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

108355360

Date of Patent

November 17, 2020

Patent Application Number

161495220

Date Filed

October 2, 2018

Patent Citations Received

‌

US Patent 11975002 Preparation and composition for treatment of malignant tumors

‌

US Patent 11690843 Preparation and composition for treatment of malignant tumors

‌

US Patent 11883404 Preparation and composition for treatment of malignant tumors

Patent Primary Examiner

‌

Dennis Heyer

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10835536 Therapeutic agent for FGFR inhibitor-resistant cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API